Emergent Biosolutions
EBS
290 hedge funds and large institutions have $2.82B invested in Emergent Biosolutions in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 109 increasing their positions, 108 reducing their positions, and 83 closing their positions.
1% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 108
0.17% less ownership
Funds ownership: 83.73% → 83.56% (-0.17%)
14% less funds holding
Funds holding: 339 → 290 (-49)
28% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $15.8M
32% less capital invested
Capital invested by funds: $4.14B → $2.82B (-$1.32B)
59% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 83
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$57.1M |
| 2 |
EARNEST Partners
Atlanta,
Georgia
|
+$42.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.7M |
| 4 |
Two Sigma Investments
New York
|
+$27.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$46.8M |
| 2 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$28.7M |
| 3 |
Lazard Asset Management
New York
|
-$23.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$23.4M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$23.2M |
EBS Hedge Fund Activity: Q2 2021 in Review
290 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2021, worth a combined $2.82B — down 32% from $4.14B a quarter earlier.
Sellers outnumbered buyers: 83 funds closed out of EBS and 34 opened new positions — a net loss of 49 holders — while 108 trimmed existing stakes and 109 added.
The largest buyer was Janus Henderson Group, adding an estimated $57.1M. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $46.8M sold.
- 290 institutional investors held Emergent Biosolutions (EBS) as of Q2 2021, down from 339 in Q1 2021.
- Funds reported $2.82B of Emergent Biosolutions stock for Q2 2021, down 32% quarter-over-quarter.
- 34 funds opened new Emergent Biosolutions positions in Q2 2021 and 83 closed out, a net change of -49 holders.
- The largest Emergent Biosolutions buyer in Q2 2021 was Janus Henderson Group, an estimated $57.1M added.
- The largest Emergent Biosolutions seller in Q2 2021 was Fuller & Thaler Asset Management, an estimated $46.8M sold.
Based on aggregated 13F filings for Q2 2021.